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Abstract 
Background 
To derive micronutrient recommendations in a scientifically sound way, it is important to 
obtain and analyse all published information on the association between micronutrient intake 
and biochemical proxies for micronutrient status using a systematic approach. Therefore, it is 
important to incorporate information from randomized controlled trials as well as 
observational studies as both of these provide information on the association. However, 
original research papers present their data in various ways. 
Methods 
This paper presents a methodology to obtain an estimate of the dose–response curve, 
assuming a bivariate normal linear model on the logarithmic scale, incorporating a range of 
transformations of the original reported data. 
Results 
The simulation study, conducted to validate the methodology, shows that there is no bias in 
the transformations. Furthermore, it is shown that when the original studies report the mean 
and standard deviation or the geometric mean and confidence interval the results are less 
variable compared to when the median with IQR or range is reported in the original study. 
Conclusions 
The presented methodology with transformations for various reported data provides a valid 
way to estimate the dose–response curve for micronutrient intake and status using both 
randomized controlled trials and observational studies. 
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Background 
Meta-analysis of the association between micronutrient intake and biochemical proxies for 
micronutrient status or function is needed when setting micronutrient recommendations. 
Information on this association may come from randomized controlled trials as well as from 
observational studies. In a randomized trial subjects are randomized to receive either the 
intervention treatment or the control treatment, and a meta-analysis of such studies will 
usually provide a mean difference in micronutrient status between placebo and intervention 
groups, answering the question whether the biochemical status marker responds to the dietary 
intake of a micronutrient [1-3]. However, this analysis does not provide an estimate of the 
slope of the dose–response relationship. On the other hand, a meta-analysis of observational 
studies provides an estimate of the slope of the dose–response relation, but observational 
studies are hampered by for instance measurement error in the intake estimates, which causes 
bias in the reported association [4-6]. 
Ideally, information from observational studies and randomized controlled trials should be 
compared or even combined in a single meta-analysis to ensure that all reported information 
is taken into account over a broad range of intake. This requires that the summary statistics 
reported in individual studies are transformed into estimates of the dose–response relation. 
Since both intake and status are continuous variables, this estimate is actually an estimate of 
the regression coefficient of the linear regression of micronutrient status on micronutrient 
intake. The individual estimates of the dose–response regression coefficient may then be 
combined in a meta-analysis. 
The statistical combination of study results may be complicated by the variety of ways that 
individual studies report the summary statistics. The results from randomized controlled trials 
as well as the baseline summary statistics of micronutrient intake and status may be reported 
as means, medians or geometric means. Variability is often reported as standard deviations, 
standard errors, interquartile ranges (IQR), ranges or confidence intervals (CI). In 
observational studies the relation between intake and status can be reported as a Pearson 
correlation coefficient, a Spearman rank correlation coefficient or a regression coefficient. In 
addition, either the intake variable or the status variable or both could have been 
logarithmically transformed before the correlation or association was calculated. All these 
different ways of reporting need to be standardized before meta-analysis is even possible. 
This paper gives an overview of transformation methods to algebraically derive an estimate 
from each study of the regression coefficient (slope, b) and its standard error (se(b)), for 
studies that do not directly report these. The methods are validated by comparing the 
calculated values with theoretical values in a small-scale simulation study. 
Methods 
MethodsIn order to derive transformations we assume a bivariate normal distribution on the 
log-scale for intake and status of an individual person. The log-scale was chosen because 
both intake and status values are always above zero, and the observed distributions of the 
micronutrient variables are often right-skewed. Moreover, as the true shape of the dose–
response curve is usually unknown the linear relation between logarithmically transformed 
quantities provides the simplest approximation. 
More in detail, for the dose–response meta-analysis of observational studies we assume that 
0ξ  (intake of micronutrient) and 0η  (status or continuous health outcome) are log-normally 
distributed. The assumption of bivariate normality entails a linear association between 
)ln( 0ξξ = and )ln( 0ηη = , where ln denotes the natural logarithm. Note that we use the 
Greek letters ξ and η for the theoretical values of intake and status/response, and the Latin 
letters X and Y for the observed values of these variables. Furthermore, we reserve letters 
without subscript (e.g. X and Y) for values expressed on the ln-scale, and use letters with 
subscript 0 (e.g., X0 and Y0) for values expressed on the absolute (i.e., original) scale. 
The process of data transformations to obtain the required statistics from what is reported in 
observational studies, consists of four steps (Figure 1). The first step is to obtain the mean of 
X (mX) and Y (mY) and the standard deviation of X (sX) and Y (sY). Secondly, the mean of 
X0 (mX0) and Y0 (mY0) and the standard deviation of X0 (sX0) and Y0 (sY0) are calculated 
when needed for the calculations in step 3. In this third step the correlation coefficient of the 
association between X and Y (rXY) is calculated from the reported data. In the last step, the 
regression coefficient of the linear regression from Y on X (bYX) is calculated from rXY, 
and the se(bYX) is calculated from rXY, sY, sX and the sample size (n). For reports on 
randomized controlled trials, the process consists of three steps. In the first step, mY and sY 
are obtained for both intervention and placebo group. In the second step, mX is obtained, and 
in the last step, bYX and se(bYX) are calculated. The equations for all these transformations 
are given below. 
Figure 1 Flowchart indicating the process of data transformations. m, mean, s, standard 
deviation, b, regression coefficient, r, correlation coefficient. X indicates intake of 
micronutrient and Y indicates a proxy for micronutrient status or continuous health outcome. 
Capital letters without subscript are used for values expressed on the ln-scale and small letters 
with subscript 0 for values expressed on the absolute scale 
Univariate transformations 
First, we describe how the univariate statistics of the normal distributions at the ln-scale can 
be obtained from various reported statistics. We present formulas for mX and sX, which of 
course can also be used similarly for mY and sY in observational studies. For randomized 
controlled trials the situation is different, because the variation in X is artificial and is not 
described by a normal distribution. Therefore, the transformations should be used only to 
obtain mY and sY in the intervention and placebo groups separately. In most trials the within-
group variation in X will be ignorable compared with the difference between the groups, 
consequently mX is calculated simply as mXcon = ln(mX0_con) for the placebo group and as 
mXint = ln(mX0_int) the intervention group. 
For these transformations, we assume that ξ  is normally distributed with parameters ξµ and 
ξσ . For a lognormal distribution the mean on the absolute scale, 0ξµ , is given by ( )25.0exp
0 ξξξ σµµ +=  and the standard deviation on the absolute scale, 0ξσ , is given by 
( ) ( ) 1exp5.0exp 22
0
−+= ξξξξ σσµσ . It follows that when the mean (mX0) and the standard 
deviation (sX0) are reported, mX can be calculated as: 
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The exponential function of the mean of the lognormal distribution is equal to the median on 
the absolute scale. Therefore, when the median (medX0) has been reported on the absolute 
scale, mX is calculated as: 
)ln(medXmX 0=  (3) 
As a measure of variability an IQRx or range (rangex) is often reported together with the 
median or mean. The IQR is the difference between the third quartile Q3 and first quartile Q1 
(the 75th percentile and the 25th percentile). Basically, there are two cases. If the lower and 
upper limits are reported as such, the difference between the ln-transformed limits may be 
equated to an appropriate multiple of the standard deviation sX. On the other hand, if only the 
IQR or range is reported as such, the derivation is more complex. When IQRX0 is reported 
together with the median, the relation between these and sX is given by 
( ) ( )[ ]sXzexpsXzexpmedXIQRX 00 ⋅−−⋅×= , where z represents the appropriate 
percentage point in the standard normal distribution (i.e., z0.75 = 0.6745). 
In this case sX may be calculated as 
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(4) 
When the IQR is reported together with the mean no explicit formula exists to derive sX. 
Therefore, to obtain an estimate of sX from these quantities a nonlinear function optimization 
is employed to find the value of sX for which the following equation holds 
( ) ( ) ( )[ ]sXzexpsXzexpsX5.0expmXIQRX 200 ⋅−−⋅×−×=  (5) 
When the lower and upper bounds of the IQR (i.e., Q1(X0) and Q3(X0) respectively) are 
reported, rather than the difference, sX may be calculated as [ ] 2z)X(Q)X(QsX 13 −=  
The range is the difference between the maximum and the minimum value of the data. 
Equations (4) and (5) may be similarly used when the range is reported, but here we consider 
that the minimum and the maximum represent the lower and upper (1/n) fraction of the 
dataset of n observations. Therefore we expect a fraction p = 1-1/(2n) below the minimum and 
the same fraction above the maximum, and in the equations above we need to use zp. For 
example, in a dataset with n = 100 we use z0.995 = 2.576. 
The geometric mean (gm) of the lognormal distribution is equal to exp(mX), and is most 
often reported in papers together with the 95% confidence limits. mX and sX are obtained for 
these quantities using: 
)ln(gmXmX 0=  (6) 
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where X0,upp is the upper limit, X0,low is the lower limit of the 95% confidence interval and 
z0.975 = 1.96 represents the 97.5th percentage point in the standard normal distribution. 
Then in step 2 for observational studies, mx and sx are calculated in case these estimates 
were not already available. These statistics at the original scale may be needed in the 
bivariate transformations described below. The equations are: 
)0.5sXexp(mXmX 20 +=  (8) 
( ) 1sXexpmXsX 200 −×=  (9) 
Bivariate transformations (to obtain regression or correlation coefficients) 
For observational studies, the next step is to obtain an estimate of the correlation between X 
and Y (rXY). The equations below can be used to obtain rXY from reported correlation and 
regression coefficients taking into account the possibility that either X0, log10(X0), X, Y0, 
log10(Y0) or Y was used for the originally reported statistic. 
When a study reports the association as a Spearman rank correlation coefficient (rS), rXY is 
calculated as 
s
rrXY =
 (10) 
Another option is that the association between X0 and Y0 is reported as a regression 
coefficient (bY0X0). In that case the correlation coefficient, rX0Y0, is calculated first using 
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and then rXY is calculated using the following equation which was derived from Johnson & 
Kotz [7]: 
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This formula (12) is also used when the Pearson product–moment correlation coefficient 
rX0Y0 is directly reported in a paper. 
For observational studies that report the regression coefficient between Y0 and X, the 
correlation coefficient, rXY0, is calculated using 
0
00
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(13) 
When log10(X0) is used instead of X, sX is replaced by sX/ln(10) in formula (13). 
Then rXY is calculated using the following equation [8,9]: 
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This formula (14) is also used when rXY0 is reported directly or when the Pearson product–
moment correlation coefficient is reported between log10(X0) and Y0. 
When the regression coefficient between Y and X0 is reported in an observational study, the 
regression coefficient, rX0Y, is calculated using 
sY
sXbYXYrX 000 ×=  (15) 
When log10(Y0) is used instead of Y, sY is replaced by sY/ln(10) in formula (15). 
Using rX0Y or the directly reported Pearson product–moment correlation coefficient between 
X0 and log10(Y0) or Y in an observational study, rXY is calculated using [8,9]: 
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When the regression coefficient between X and Y is reported, rXY is calculated as 
sY
sXbYXrXY ×=
 
(17) 
Calculation of dose–response regression coefficient 
In the last step, for both observational studies and randomized controlled trials, we need to 
obtain bYX and se(bYX). For observational studies, the required regression coefficient bYX 
is calculated from the correlation coefficient: 
sX
sY
rXYbYX ×=
 
(18) 
and the corresponding standard error (se(bYX)) is calculated as 
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For randomized controlled trials, the required regression coefficient bYX is calculated as: 
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where ‘int’ indicates the intervention group and ‘con’ indicates the control or placebo group. 
The corresponding standard error is calculated as: 
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Simulation study 
A simulation study was conducted to validate the performance of the transformations given in 
this paper. Bivariate lognormal data (X,Y) were simulated where X ~ Normal(1.60,0.852) and 
Y ~ Normal(5.70,0.452). Parameter values were based on values of vitamin B12 intake (X) 
and serum/plasma vitamin B12 (Y) [10-13]. Different strengths of the correlation between X 
and Y were simulated, namely 0.1, 0.5 and 0.9. 
A sample of individuals (with sample size 100, 200 or 500) was randomly drawn, and values 
that represent different often used reporting options were calculated from this sample, namely 
the mean and SD, the median and IQR, the median and range and the geometric mean and 
95% CI (all summary statistics on the absolute scale). Also, the correlation and regression 
coefficients of X and Y expressed in different scales were calculated. These ‘reported’ values 
were rounded to two decimal places. From these ‘reported’ values, the parameter estimates 
mX, mY, sX, sY and rXY were calculated using the transformations described in this paper. 
This process was repeated 1000 times. 
Results 
Table 1 shows the simulation results for the univariate statistics. On average the calculated 
values of mX and mY are almost the same as the true values, indicating that no important 
bias is present in these calculations. As expected, the 95% CI of the simulations is smaller for 
the simulations with a sample size of 500 than for the simulations with a sample size of 200 
or 100. For sX and sY, the estimates are most precise when a geometric mean with a 95% CI 
is reported, and least precise when a median with a range is reported. 
Table 1 Simulation results for mX, sX, mY and sY 
 n mX sX mY sY 
True  1.6 0.85 5.7 0.45 
Mean, SD 100 1.6 (1.4-1.8) 0.82 (0.65-1.06) 5.7 (5.6-5.8) 0.45 (0.37-0.53) 
200 1.6 (1.4-1.7) 0.83 (0.70-1.03) 5.7 (5.6-5.8) 0.45 (0.40-0.51) 
500 1.6 (1.5-1.7) 0.84 (0.75-0.98) 5.7 (5.7-5.7) 0.45 (0.42-0.49) 
Median, IQR 100 1.6 (1.4-1.8) 0.84 (0.63-1.10) 5.7 (5.6-5.8) 0.44 (0.35-0.56) 
200 1.6 (1.5-1.8) 0.85 (0.70-1.02) 5.7 (5.6-5.8) 0.45 (0.38-0.53) 
500 1.6 (1.5-1.7) 0.85 (0.76-0.95) 5.7 (5.7-5.7) 0.45 (0.40-0.50) 
Median, range 100 1.6 (1.4-1.8) 0.83 (0.58-1.14) 5.7 (5.6-5.8) 0.44 (0.32-0.60) 
200 1.6 (1.5-1.8) 0.83 (0.63-1.12) 5.7 (5.6-5.8) 0.44 (0.35-0.58) 
500 1.6 (1.5-1.7) 0.83 (0.68-1.06) 5.7 (5.7-5.7) 0.44 (0.36-0.56) 
Gm, 95% CI 100 1.6 (1.4-1.8) 0.85 (0.73-0.97) 5.7 (5.6-5.8) 0.45 (0.38-0.51) 
200 1.6 (1.5-1.7) 0.85 (0.77-0.94) 5.7 (5.6-5.8) 0.45 (0.41-0.49) 
500 1.6 (1.5-1.7) 0.85 (0.80-0.90) 5.7 (5.7-5.7) 0.45 (0.42-0.48) 
Figure 2 shows the simulation results when a correlation coefficient is reported, and Figure 3 
shows the simulation results when a linear regression coefficient is reported. Both these 
figures show the simulation results with true rXY = 0.5. Results are similar for true rXY = 0.9 
and true rXY = 0.1 (data not shown). For the situation in which a correlation coefficient is the 
reported bivariate statistic, there is no difference for the four univariate reporting options. 
Therefore, these results are pooled in Figure 2. 
Figure 2 Simulation results for rXY where the true rXY was 0.5. Circles indicate that the 
reported bivariate statistic was rX0Y0, squares indicate rXY0 and diamonds indicate rX0Y. 
Bars represent 95% confidence intervals. In each group the three bars from left to right are 
for sample sizes of 100, 200 and 500 individuals, respectively. 
Figure 3 Simulation results for rXY from different reporting options where the true 
rXY was 0.5. A) b from linear regression of Y0 on X0; B) b from linear regression of Y 
on X0; C) b from linear regression of Y0 on X; D) b from linear regression of Y on X and 
from the linear regression of log10(Y0) on log10(X0). Circles indicate that the reported 
univariate statistic was mean + SD, squares indicate median and IQR, diamonds indicate 
median and range, and triangles indicate geometric mean. Bars represent 95% confidence 
intervals. In each group the three bars from left to right are for sample sizes of 100, 200 and 
500 individuals, respectively 
None of the combinations of univariate and bivariate reporting options shows evidence of 
bias with the average of the simulations almost equal to the true value. The width of the 
confidence interval indicates the variability of the simulations. Because there is no 
appreciable bias, a smaller CI width indicates that the individual simulations are closer to the 
true correlation. The accuracy is best when rxY is reported and worst when rxy is reported. 
As expected, the accuracy is also better when the sample size is larger. Figure 3 shows that 
the CI is wider when the reported univariate statistics are the median and IQR or median and 
range. The larger variation in the results for the transformation from bYx (Figure 3B) 
compared with the variation in the results from byX (Figure 3C) is caused by the fact the X 
was simulated with larger standard deviation than Y. 
Example 
To illustrate the methodology some examples of its use on real data for vitamin B12 are 
reported in Table 2 (observational studies [14,15]) and Table 3 (randomized controlled trials 
[16,17]). The tables show the statistics as reported in the studies and the statistics that are 
calculated using the different equations presented in this paper (which are entitled ‘required 
statistics’ in the tables). 
Table 2 Example statistics for observational studies on vitamin B12 intake (X) and vitamin B12 status (Y) 
Reference Observed univariate statistics Observed bivariate  
statistic 
Required statistics 
Type X0 and Y0 X0 Y0 n Association mX sX mY sY rXY bYX se(bYX) 
[14] Mean, SD 9.3, 9.3 330, 140 177 rX0Y0 0.16 1.88 0.83 5.72 0.41 0.19 0.09 0.04 
[15] gm, 95% CI 7.3, 7.1-7.5 354, 348-360 1329 rs 0.19 1.99 0.51 5.87 0.32 0.19 0.12 0.02 
 
 
 
Table 3 Example statistics for randomized controlled trials on vitamin B12 intake and vitamin B12 status 
Reference  Observed univariate statistics Required statistics 
 X0* Type Y0 Y0 n mX mY sY bYX se(bYX) 
[16] intervention 405 mean, SD 379, 189 17 6.00 5.83 0.47 0.12 0.03 
control 5 mean, SD 211, 77 17 1.61 5.29 0.35 
[17] intervention 505 med, IQR 198, 158-271 20 6.22 5.29 0.40 0.13 0.04 
control 5 med, IQR 110, 73-165 20 1.61 4.70 0.60 
*) X0 represents the dose provided plus the dietary intake. When dietary intake of vitamin B12 was not reported 5 µg/day was added to the 
provided dose. The 5 µg/day was calculated as the average dietary intake from several studies 
 
 
Discussion 
The investigated means, standard deviations, correlation coefficients and sample sizes were 
based on real-life values. The univariate statistics that are investigated in this paper were 
limited to mean and SD, median and IQR or range and geometric mean and 95% CI. These 
do not represent all reporting options that can be encountered in the literature, but cover most 
published papers. Other combinations of univariate statistics that were seen are for example 
mean with IQR, mean with range, and geometric mean with standard deviation. Also, the 
investigated regression and correlation coefficients are limited in this paper to those on the 
absolute or logarithmic scale, whereas sometimes other transformations to normality have 
been used in reports, such as a square root transformation. However, as the logarithmic 
transformation is by far the most often used transformation in papers in the medical research 
area, the equations in this paper will cover most published papers in this field. 
The bivariate normal linear model on the logarithmic scale is an approximation that is used 
here because the data are positive data. Note that it allows the relationship between X0 and Y0 
to be a linear, monotonic convex or monotonic concave function (i.e., for a slope equal, 
higher or lower than one, respectively). Even though some randomized controlled trials may 
investigate the dose–response relationship by providing multiple dosages in their study, most 
of these studies include only one intervention and one control group and consequently it is 
often unknown what the true relationship is. Therefore, this approximation provides a 
practical methodology to estimate the dose–response relationship and to combine the results 
from randomized controlled trials and observational studies. It was outside the scope of the 
simulation study to investigate other shapes of the dose–response relation. 
The transformations in this paper consider reported regression and correlation coefficients 
that are unadjusted for other variables. It is possible to adjust the equations for adjusted 
regression or correlation coefficients, if these adjustments were done on the log-scale. 
However, most often adjustment has been done on another scale, and moreover studies do not 
report all required statistics. Therefore, we did not consider adjusted coefficients. 
In this paper we presented a methodology that allows for information from RCTs and 
observational studies to be summarised in comparable statistics. One possible application is 
to combine results of both types of study in a single meta-analysis. In general, a meta-
analysis should include as much information as possible. However, there may be systematic 
differences between observational studies and randomized controlled trials. Therefore, it is 
advisable to check whether the size of the estimated regression coefficient differs between 
this different study designs. This may be done by stratified analysis or by using meta-
regression techniques. 
Conclusions 
The presented methodology provides calculations to use results from published literature to 
estimate the slope of the dose–response relation incorporating information from both 
randomized controlled trials and observational studies. The simulations clearly show that 
there is no observable bias associated with the transformations. Also, it can be seen that when 
a regression coefficient is reported, it is preferable to report the univariate statistics as mean 
and SD or geometric mean and 95% CI rather than as median with IQR or range. 
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Step 1 
Calculate mX, sX and mY, sY from 
reported univariate statistic using 
equations (1)-(7) 
Step 2 
Calculate mX0, sX0 and mY0, sY0 from 
mX, sX and mY, sY: equations (8), (9) 
Step 3 
Calculate rXY from reported bivariate 
statistic using equations (10)-(17) 
Step 4 
Calculate bYX from rXY: equation 
(18) 
Calculate se(bYX): equation (19) 
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TRIALS 
Step 1 
Calculate mY and sY from reported 
values after intervention for placebo 
and intervention group using 
equations (1)-(7) 
Step 2 
Calculate mX as ln(mX0) for both 
placebo and intervention group 
Step 3 
Calculate bYX: equation (20) 
Calculate se(bYX): equation (21) 
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